BRAF and metastatic colorectal cancer: Aberrant alterations in the HER2 gene are relatively uncommon in metastatic colorectal cancer, with HER2 gene amplification present in approximately 3% of metastatic colorectal cancers, mostly in RAS/BRAF wild-type patients (Ross et al., 2018).